(Q57449141)

English

C-peptide an adequate endpoint in type 1 diabetes

scholarly article by Johnny Ludvigsson published November 2009 in Diabetes - Metabolism: Research and Reviews

In more languages

default for all languages

No label defined

No description defined

edit

Statements

0 references

0 references

C-peptide an adequate endpoint in type 1 diabetes (English)

0 references

0 references

0 references

Johnny Ludvigsson

1

0 references

publication date

November 2009

0 references

published in

Diabetes - Metabolism: Research and Reviews

0 references

volume

25

0 references

issue

8

0 references

page(s)

691-693

0 references

cites work

Radioimmunological determination of human C-peptide in serum

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

C-peptide in children with juvenile diabetes. A preliminary report.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

C-peptide is a bioactive peptide

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

GAD treatment and insulin secretion in recent-onset type 1 diabetes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2FDMRR.1035

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/DMRR.1035

0 references

PubMed publication ID

19877135

0 references

(Q57449141)

C-peptide an adequate endpoint in type 1 diabetes

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)